Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Talquetamab vs Belantamab Mafodotin in Relapsed/Refractory Multiple Myeloma
NCT05461209Phase 3Withdrawn
- Sponsor
- Janssen Pharmaceutical
- Start
- Oct 2022
- Primary completion
- Nov 2022
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 2
01
Overview
A Phase 3 trial of talquetamab in multiple myeloma (MM), sponsored by Janssen Pharmaceutical. Planned start Oct 2022; status: withdrawn.
02
Drugs
talquetamab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT05461209.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05461209.